What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021
Fabio Turco(Ente Ospedaliero Cantonale), Piet Ost(Ghent University Hospital), Rob Jones(University of Manchester), Kim N.(Asian Institute of Technology), Karim Fizazi(Université de Lille), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Laurence Klotz(Sunnybrook Health Science Centre), Anders Bjartell(Lund University), Michael J. Morris(Dana-Farber Cancer Institute), Felix Y. Feng(University of Michigan), Robert G. Bristow(Princess Margaret Cancer Centre), Nicholas D. James(Royal Marsden NHS Foundation Trust), Orazio Caffo(Ospedale Santa Chiara), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Raja B. Khauli(American University of Beirut Medical Center), Ignacio Durán(Instituto de Biomedicina de Sevilla), Ravindran Kanesvaran(University of Ioannina), Andrew J. Armstrong(Duke University), Raya Leibowitz‐Amit(The University of Texas MD Anderson Cancer Center), Himisha Beltran(Dana-Farber Cancer Institute), Tomasz M. Beer(Exact Sciences (United States)), Jason A. Efstathiou(Massachusetts General Hospital), Vedang Murthy(Homi Bhabha National Institute), Caroline S. Clarke(The Royal Free Hospital), Susan Halabi(Duke Medical Center), Nicolas Mottet(Centre Hospitalier Universitaire de Saint-Étienne), Hind Mrabti(Institut National d'Oncologie), Stefano Fanti(Azienda USL di Bologna), Muhammad Bulbul(American University of Beirut Medical Center), Martin Gleave(University of British Columbia), Michael S. Hofman(Peter MacCallum Cancer Centre), Ian D. Davis(Austin Health), Noel W. Clarke(The Christie NHS Foundation Trust), Mark Frydenberg(Monash University), Alicia K. Morgans(Dana-Farber Cancer Institute), Johann S. de Bono(Royal Marsden NHS Foundation Trust), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Christopher P. Evans(University of Nevada, Reno), Ngozi Ekeke Onyeanunam(University of Port Harcourt Teaching Hospital), Declan G. Murphy(Peter Doherty Institute), Alberto Bossi(Institut Gustave Roussy), Daniel Heinrich(San Antonio College), Dan George(Duke University), Maha Hussain, Fernando Cotait Maluf(Hospital Israelita Albert Einstein), Gerhardt Attard(London Cancer), Robin Millman(MRC Clinical Trials Unit at UCL), Celestia S. Higano(University of British Columbia)
Cited by 9
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k